Call for clinical trials in brain metastases (RFA BM)Funder(s): Anticancer Fund,
This RFA seeks to increase clinical trial activities in patients diagnosed with Brain Metastases (BM), including Leptomeningeal metastases (LM). We are looking for innovative approaches that can improve survival rate in this specific patient population. The focus is on clinical trials assessing interventions that can increase survival or induce durable responses.
Despite of numerous registered trials and efforts in this patient population, there is still a high need of new and successful treatment options due to the rate of uncompleted and terminated trials. To limit trial execution failure, prioritisation will be given to applicants that have successfully conducted clinical trials in this patient population in the past and have a track record in conducting clinical trials in BM and/or LM.
Timeline & Milestones
February 8, 2022
Deadline First stage (LOI / pre-proposal)
May 1, 2022
Announcement of Applicants selected for stage 2
June 1, 2022
Deadline Full Application
September 1, 2022
Grant Decision – Final Decision – Awarding
October 31, 2022